Kymera in the News

Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).

A group of aspiring young scientists got a glimpse inside a Watertown company that does cutting-edge biopharmaceutical research.

Nello Mainolfi explains the concept of protein degradation and describes three key technologies that enable precision protein measurement

With more attention being paid to work-life balance and employee burnout, a slower summer may not be a bad thing. The biopharma industry in particular is often go-go-go, but industry leaders still look for ways to stop and smell the roses while keeping innovation on track.

Kymera and Sanofi plan to move ahead with the skin drug that the French drugmaker paid $150 million in cash in 2020 to partner on, after positive Phase I results on the IRAK4 degrader they’ve been working on for a pair of skin conditions.

Sanofi will advance an experimental inflammatory disease drug into Phase 2 clinical testing after its biotechnology company partner Kymera Therapeutics reported Wednesday what it described as encouraging results from a small study.

Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa (HS) and atopic dermatitis (AD), breaking ground to take protein degradation outside the field of oncology and into inflammatory disease indications.

KYMR announced positive clinical data from a phase I study evaluating its highly selective, orally bioavailable IRAK4 degrader, KT-474, for the treatment of patients with hidradenitis suppurativa (“HS”) and atopic dermatitis (“AD”).

Kymera Therapeutics has generated the first early clinical evidence that its targeted protein degradation technology works in immune-inflammatory diseases.

Kymera’s wellness stipend, instituted at the beginning of the year, is designed to let workers know “we care about them, and want to give them a way to care for themselves,” says Karen Weisbach, vice president of people and culture.